<DOC>
	<DOCNO>NCT01460069</DOCNO>
	<brief_summary>The objective study investigate effect GLP-1 analogue Victoza® psoriasis double-blinded , randomized placebo-controlled clinical trial .</brief_summary>
	<brief_title>The Effect Glucagon Like Peptide ( GLP ) -1 Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Caucasians 18 year age Plaque psoriasis PASI score &gt; 10 No treatment stable treatment psoriasis least 3 month inclusion Steady weight 3 month body mass index ( BMI ) 27 kg/m2 Normal blood pressure Spiral hormonal birth control fertile woman entire treatment period least 3 day end treatment period ( ~5 time plasma halflife ) Psoriasis arthritis Fasting plasma glucose &gt; 7.5 mmol/L HbA1c &gt; 7.5 % Type 1 diabetes Treatment type 2 diabetes GLP1based medicine ( DDP4inhibitors GLP1receptoragonists ) Heart failure , NYHA class IIIIV Uraemia , endstage renal disease , cause impair renal function screatinine &gt; 150 µM and/or albuminuria Liver disease ( alanine amino transferase ( ALAT ) and/or aspartate amino transferase ( ASAT ) &gt; 2 x upper normal serum level ) Anaemia Acute chronic pancreatitis Struma thyroid cancer Pregnancy breast feeding Inability complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>liraglutide</keyword>
	<keyword>morbidity</keyword>
	<keyword>PASI</keyword>
	<keyword>DLQI</keyword>
</DOC>